A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol

• Published in: BMC cancer Vol. 22; no. 1; pp. 1 - 827
• Main Authors: Guan, Yun, Pan, Mingyuan, Yang, Jun, Lu, Qiuxia, Han, Liangfu, Liu, Ying, Li, Jing, Zhu, Huaguang, Gong, Xiu, Mei, Guanghai, Liu, Xiaoxia, Pan, Li, Dai, Jiazhong, Wang, Yang, Wang, Enmin, Wang, Xin
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 29.07.2022; BioMed Central; BMC
• Subjects: Adjuvant chemoradiotherapy; Adjuvant treatment; Brain cancer; Brain tumors; Cancer; Care and treatment; Chemoradiotherapy; Chemotherapy; Clinical trials; Cognitive ability; Diagnosis; Disease; Glioblastoma; Glioblastoma multiforme; Hypofractionated stereotactic radiotherapy; Hypotheses; Intensity-modulated radiotherapy; Laboratories; Magnetic resonance imaging; Newly diagnosed glioblastoma; Patient outcomes; Patients; Quality of life; Radiation therapy; Radiosurgery; Risk factors; Study Protocol; Surgery; Survival; Temozolomide; Testing; Toxicity; China
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-09914-5

Background The most frequently diagnosed primary brain tumor is glioblastoma (GBM). Nearly all patients experience tumor recurrence and up to 90% of which is local recurrence. Thus, increasing the therapeutic ratio of radiotherapy using hypofractionated stereotactic radiotherapy (HSRT) can reduce treatment time and may increase tumor control and improve survival. To evaluate the efficacy and toxicity of the combination of HSRT and intensity-modulated radiotherapy (IMRT) with temozolomide after surgery in GBM patients and provide evidence for further randomized controlled trials. Methods/design HSCK-010 is an open-label, single-arm phase II trial (NCT04547621) which includes newly diagnosed GBM patients who underwent gross total resection. Patients will receive the combination of 30 Gy/5fx HSRT, and 20 Gy/10fx IMRT adjuvant therapy with concurrent temozolomide and adjuvant chemotherapy. The primary endpoint is overall survival (OS). Secondary outcomes include progression-free survival (PFS) rate, objective-response rate (ORR), quality of life (Qol) before and after the treatment, cognitive function before and after the treatment, and rate of treatment-related adverse events (AE). The combination of HSRT and IMRT with temozolomide can benefit the patients after surgery with good survival, acceptable toxicity, and reduced treatment time. Trial registration NCT04547621. Registered on 14 September 2020. Keywords: Hypofractionated stereotactic radiotherapy, Newly diagnosed glioblastoma, Adjuvant chemoradiotherapy